On September 26, 2019, Aimed Alliance delivered oral testimony on the Institute for Clinical and Economic Review’s (ICER) Evidence Report on Additive Therapies for Cardiovascular Disease: Effectiveness and Value. We thanked ICER for deeming both icosapent ethyl and rivaroxaban to be cost effective and responsibly priced. We also highlighted our concerns that (1) the Evidence Report would impact patient access by encouraging the use of prior authorization and other benefit utilization management policies, (2) ICER did not incorporate several important considerations into its potential budget impact analysis and value-based benchmark prices, and (3) ICER’s use of QALYs will result in inappropriate health care rationing and discrimination. ICER’s Final Evidence Report is due out October 17, 2019.
Last Updated on May 15, 2020 by Aimed Alliance
